Outcomes and Treatment Approaches for Stage III Inflammatory versus Noninflammatory Breast Cancer

Overview

This study examines the use of trimodality therapy (TMT) in stage III inflammatory breast cancer (IBC) compared to non-IBC, revealing a decline in TMT use over time and consistently poorer survival outcomes for IBC. Despite advancements in systemic therapies, disparities in breast cancer-specific survival (BCSS) and overall survival (OS) persist between IBC and non-IBC.

Background

Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer characterized by rapid onset of symptoms. Historically, patients with IBC have experienced worse clinical outcomes compared to those with non-IBC. Understanding treatment trends and survival outcomes is crucial for improving care and addressing disparities in this patient population.

Data Highlights

Key Findings

• IBC patients had inferior BCSS and OS compared to non-IBC patients across all tumor subtypes.
• The use of TMT for IBC declined from 33.9% in 2010 to 24.2% in 2020.
• Survival outcomes for IBC did not improve over the decade studied.
• De-escalation of treatment in IBC has not been shown to be safe, contrasting with trends in non-IBC.
• Current guidelines emphasize aggressive local-regional management for IBC, including TMT.

Clinical Implications

Healthcare professionals should continue to adhere to guideline-concordant TMT for patients with IBC to optimize survival outcomes. Awareness of the declining use of TMT and its implications on patient survival is essential for improving treatment strategies.

Conclusion

The findings highlight the need for continued emphasis on effective treatment approaches for IBC, as disparities in survival outcomes remain significant compared to non-IBC. Further research is warranted to explore the factors contributing to these trends.

References

1. JAMA Network, JAMA Network Open, 2023 -- Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer
2. The ASCO Post — Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer
3. The ASCO Post — Impact of Empirical Dietary Inflammatory Pattern on Survival Outcomes in Patients With Stage III Colon Cancer
4. The ASCO Post — Highlights From the 2021 San Antonio Breast Cancer Symposium Guest Editors
5. The ASCO Post — New Approaches Needed for Patients With Locoregional Breast Cancer Progression During Neoadjuvant Systemic Therapy
6. NCCN Guidelines® Insights - Breast Cancer, Version 5.2025
7. Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer | Cancer Biomarkers | JAMA Network Open | JAMA Network
8. Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer - The ASCO Post